ArQule (ARQL) dives 64% premarket following the discontinuation of its Phase 3 MARQUEE (c-Met...


ArQule (ARQL) dives 64% premarket following the discontinuation of its Phase 3 MARQUEE (c-Met inhibitor ARQ 197) trial. "We are disappointed that the MARQUEE trial did not provide statistically significant results." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs